ASX - By Stock
|
NOX |
Re:
Ann: March 2022 Quarterly Activities Report and Appendix 4C
|
|
Stayso 54
|
74 |
26K |
0 |
30/04/22 |
30/04/22 |
ASX - By Stock
|
74
|
26K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Announces Leadership Transition
|
|
Stayso 54
|
26 |
10K |
14 |
23/02/22 |
23/02/22 |
ASX - By Stock
|
26
|
10K
|
14
|
|
ASX - By Stock
|
NOX |
Wainwright Presentation Recording
|
|
Stayso 54
|
2 |
1.7K |
11 |
12/01/22 |
12/01/22 |
ASX - By Stock
|
2
|
1.7K
|
11
|
|
ASX - By Stock
|
NOX |
Investor Video Noxopharm 2021 AGM
|
|
Stayso 54
|
6 |
2.0K |
12 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
6
|
2.0K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm 2021 AGM Corporate Presentation
|
|
Stayso 54
|
10 |
4.2K |
3 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
10
|
4.2K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Retraction of Grant Announcement
|
|
Stayso 54
|
57 |
19K |
12 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
57
|
19K
|
12
|
|
ASX - By Stock
|
NOX |
New CEO Blog on NOX Website
|
|
Stayso 54
|
1 |
543 |
8 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
1
|
543
|
8
|
|
ASX - By Stock
|
NOX |
Noxopharm Podcast
|
|
Stayso 54
|
16 |
4.6K |
9 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
16
|
4.6K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Observations
|
|
Stayso 54
|
8 |
2.7K |
5 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
8
|
2.7K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Chemotherapy patent allowed in Europe
|
|
Stayso 54
|
5 |
1.9K |
1 |
09/10/21 |
09/10/21 |
ASX - By Stock
|
5
|
1.9K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
Stayso 54
|
15 |
5.2K |
10 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.2K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Radiotherapy Improvements ALLOWED
|
|
Stayso 54
|
25 |
6.9K |
8 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
25
|
6.9K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Radiotherapy Improvements ALLOWED
|
|
Stayso 54
|
25 |
6.9K |
4 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
25
|
6.9K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Radiotherapy Improvements ALLOWED
|
|
Stayso 54
|
25 |
6.9K |
2 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
25
|
6.9K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Radiotherapy Improvements ALLOWED
|
|
Stayso 54
|
25 |
6.9K |
4 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
25
|
6.9K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm 2021 Annual Report
|
|
Stayso 54
|
7 |
2.7K |
8 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
7
|
2.7K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
Stayso 54
|
71 |
23K |
5 |
20/08/21 |
20/08/21 |
ASX - By Stock
|
71
|
23K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
Stayso 54
|
71 |
23K |
12 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
71
|
23K
|
12
|
|
ASX - By Stock
|
NOX |
NOX Website Refurbished
|
|
Stayso 54
|
8 |
2.9K |
7 |
18/08/21 |
18/08/21 |
ASX - By Stock
|
8
|
2.9K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
|
|
Stayso 54
|
28 |
9.6K |
1 |
05/08/21 |
05/08/21 |
ASX - By Stock
|
28
|
9.6K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Secures Key European Patent Allowance for Veyonda
|
|
Stayso 54
|
40 |
14K |
10 |
09/07/21 |
09/07/21 |
ASX - By Stock
|
40
|
14K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Secures Key European Patent Allowance for Veyonda
|
|
Stayso 54
|
40 |
14K |
8 |
06/07/21 |
06/07/21 |
ASX - By Stock
|
40
|
14K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Corporate Presentation
|
|
Stayso 54
|
7 |
2.8K |
8 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
7
|
2.8K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Patent Grant
|
|
Stayso 54
|
46 |
13K |
1 |
15/06/21 |
15/06/21 |
ASX - By Stock
|
46
|
13K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Patent Grant
|
|
Stayso 54
|
46 |
13K |
5 |
14/06/21 |
14/06/21 |
ASX - By Stock
|
46
|
13K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
The boy who cried wolf
|
|
Stayso 54
|
13 |
4.9K |
6 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
13
|
4.9K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: DARRT-2 Study Update and Clarification
|
|
Stayso 54
|
21 |
6.1K |
4 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
21
|
6.1K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: DARRT-2 Study Update and Clarification
|
|
Stayso 54
|
21 |
6.1K |
1 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
21
|
6.1K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: DARRT-2 Study Update and Clarification
|
|
Stayso 54
|
21 |
6.1K |
6 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
21
|
6.1K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
DARRT-2
|
|
Stayso 54
|
15 |
3.9K |
11 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
15
|
3.9K
|
11
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Set to Benefit From Novartis ASCO Data
|
|
Stayso 54
|
24 |
10K |
10 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
24
|
10K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
Stayso 54
|
41 |
13K |
12 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
Stayso 54
|
41 |
13K |
5 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
5
|
|
ASX - By Stock
|
NOX |
Proactive CEO Interview
|
|
Stayso 54
|
10 |
4.5K |
9 |
20/05/21 |
20/05/21 |
ASX - By Stock
|
10
|
4.5K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Exquisite Timing
|
|
Stayso 54
|
23 |
10K |
12 |
19/05/21 |
19/05/21 |
ASX - By Stock
|
23
|
10K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Exquisite Timing
|
|
Stayso 54
|
23 |
10K |
6 |
18/05/21 |
18/05/21 |
ASX - By Stock
|
23
|
10K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Patent news
|
|
Stayso 54
|
31 |
12K |
3 |
12/05/21 |
12/05/21 |
ASX - By Stock
|
31
|
12K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Patent news
|
|
Stayso 54
|
31 |
12K |
2 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
31
|
12K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
Stayso 54
|
15 |
3.7K |
2 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
Stayso 54
|
15 |
3.7K |
7 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
15
|
3.7K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
Stayso 54
|
15 |
3.7K |
7 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
15
|
3.7K
|
7
|
|
ASX - By Stock
|
NOX |
CEO Interview 27 April
|
|
Stayso 54
|
15 |
3.7K |
3 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
15
|
3.7K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
Stayso 54
|
42 |
10K |
2 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
42
|
10K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
Stayso 54
|
42 |
10K |
8 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
42
|
10K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
Stayso 54
|
42 |
10K |
1 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
42
|
10K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
New Media Attachment
|
|
Stayso 54
|
4 |
1.8K |
5 |
19/04/21 |
19/04/21 |
ASX - By Stock
|
4
|
1.8K
|
5
|
|
ASX - By Stock
|
NOX |
New Media Attachment
|
|
Stayso 54
|
4 |
1.8K |
16 |
19/04/21 |
19/04/21 |
ASX - By Stock
|
4
|
1.8K
|
16
|
|
ASX - By Stock
|
NOX |
Re:
Company Maker?
|
|
Stayso 54
|
11 |
3.9K |
7 |
12/04/21 |
12/04/21 |
ASX - By Stock
|
11
|
3.9K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Patent Lodged for Major Septic Shock Opportunity
|
|
Stayso 54
|
16 |
7.8K |
3 |
06/04/21 |
06/04/21 |
ASX - By Stock
|
16
|
7.8K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Unable To See The Forrest For The Trees
|
|
Stayso 54
|
21 |
7.1K |
2 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
21
|
7.1K
|
2
|
|